Aug 27, 2019
DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials
Aug 14, 2019
DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering
Aug 13, 2019
DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
Jul 31, 2019
DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
Jul 24, 2019
DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme
Jul 10, 2019
DelMar Announces Relocation of Company Headquarters to San Diego
Jun 27, 2019
Delmar Pharmaceuticals Announces Termination Of Rights Offering
Jun 25, 2019
DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019
Jun 03, 2019
DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 03, 2019
DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering
May 29, 2019
DelMar Pharmaceuticals Updates Key Dates of Rights Offering
May 20, 2019
DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
May 08, 2019
DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
Apr 04, 2019
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
Feb 20, 2019
DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
Nov 20, 2018
DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting
Nov 14, 2018
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results
Oct 10, 2018
DelMar Announces Further Validation of the Mechanism of Action of VAL-083
Sep 24, 2018
DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results
Sep 04, 2018
DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor